Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 5, 2006, Pages 1277-1281

  Wiles, Jason A ^a   Song, Yongsheng ^a   Wang, Qiuping ^a   Lucien, Edlaine ^a   Hashimoto, Akihiro ^a   Cheng, Jijun ^a   Marlor, Christopher W ^a   Ou, Yangsi ^a   Podos, Steven D ^a   Thanassi, Jane A ^a   Thoma, Christy L ^a   Deshpande, Milind ^a   Pucci, Michael J ^a   Bradbury, Barton J ^a  

^a Achillion Pharmaceuticals   (United States)

Author keywords

Antibacterial; Methicillin resistant Staphylococcus aureus; Quinolone

Indexed keywords

9H ISOTHIAZOLO[5,4 B]QUINOLINE 3,4 DIONE; ANTIINFECTIVE AGENT; CIPROFLOXACIN; DNA TOPOISOMERASE IV; HETEROCYCLIC COMPOUND; ISOTHIAZOLOQUINOLONE; METICILLIN; NADIFLOXACIN; PALLADIUM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CATALYSIS; CROSS COUPLING REACTION; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; ESCHERICHIA COLI; HEP 2 CELL; HUMAN; HUMAN CELL; LARYNX CARCINOMA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; AZO COMPOUNDS; CELL LINE, TUMOR; CYCLIZATION; FLUORINE; HUMANS; METHICILLIN RESISTANCE; MOLECULAR STRUCTURE; QUINOLONES; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS;

ENTEROCOCCUS; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 31344436473     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.11.064     Document Type: Article

References (19)

1. Chu, D. T. U.S. Patent 4,687,770, 1987.
2. Chu, D. T. U.S. Patent 4,689,325, 1987.
3. Chu, D. T. W.; Fernandes, P. B.; Claiborne, A. K.; Shen, L.; Pernet, A. G. In Quinolones. Proceedings of an International Telesymposium; Fernandes, P. B., Ed.; Prous Science Publishers: Barcelona, Spain, 1989.
4. Domagala, J. M.; Hagen, S. E. In Quinolone Antimicrobial Agents, 3rd ed.; Hooper, D. C., Rubenstein, R., Eds.; ASM: Washington, DC, 2003; pp 3-18.
5. D.T.W. Chu, P.B. Fernandes, A.K. Claiborne, L. Shen, and A.G. Pernet Drugs Exp. Clin. Res. 14 1988 379
6. D.T.W. Chu, I.M. Lico, A.K. Claiborne, J.J. Plattner, and A.G. Pernet Drugs Exp. Clin. Res. 16 1990 215
7. Chu, D. T. U.S. Patent 4,767,762, 1988.
8. W.E. Kohlbrenner, N. Wideburg, D. Weigl, A. Saldivar, and D.T.W. Chu Antimicrob. Agents Chemother. 36 1992 81
9. Chu, D. T.-W.; Plattner, J. J.; Shen, L. L.; Klein, L. L. U.S. Patent 5,071,848, 1991.
10. J.A. Wiles, Q. Wang, E. Lucien, A. Hashimoto, Y. Song, J. Cheng, C.W. Marlor, Y. Ou, S.D. Podos, J.A. Thanassi, C.L. Thoma, M. Deshpande, M.J. Pucci, and B.J. Bradbury Bioorg. Med. Chem. Lett. 16 2006 1272
11. Culbertson, T. P.; Domagala, J. M.; Hagen, S. E.; Hutt, M. P.; Nichols, J. B.; Mich, T. F.; Sanchez, J. P.; Schroeder, M. C.; Solomon, M.; Worth, D. F. In Quinolones. Proceedings of an International Telesymposium; Fernandes, P. B., Ed.; Prous Science Publishers: Barcelona, Spain, 1989.
12. Procedures to prepare these bromides are cited below with their corresponding ITQ analogues. 10 and 11: D.E. Pearson, W.W. Hargrove, J.K.T. Chow, and B.R. Suthers J. Org. Chem. 26 1961 789
13. 21: H. Takalo, P. Pasanen, and J. Kankare Acta Chem. Scand. 42B 1988 373
14. 22: T. Talik, Z. Talik, and H. Ban-Oganowska Synthesis 1974 293
15. 34: F.T. Tyson J. Am. Chem. Soc. 61 1939 183
16. T. Ishiyama, M. Murata, and N. Miyaura J. Org. Chem. 60 1995 7508
17. P.R. Parry, C. Wang, A.S. Batsanov, M.R. Bryce, and B. Tarbit J. Org. Chem. 67 2002 7541
18. Aldehyde 41 was prepared as described previously. See: X. Wang, P. Rabbat, P. O'Shea, R. Tillyer, E.J.J. Grabowski, and P.J. Reider Tetrahedron Lett. 41 2000 4335
19. MICs were determined as described by the NCCLS (see National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing: 11th informational supplement. Vol. 21, no. 1, M100-S11. National Committee for Clinical Laboratory Standards, Wayne, PA). The MIC was defined as the lowest concentration of each compound resulting in inhibition of visible growth of bacteria after incubation at 37°C for 18-24 h.